Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anshen Jielv granule is a Traditional Chinese Medicine (TCM) formula developed by Xuanwu Hospital of Capital Medical University for the treatment of generalized anxiety disorder (GAD). It is a granule-based herbal preparation designed for oral administration. The formula is typically utilized within the framework of TCM syndrome differentiation, often targeted at patients exhibiting symptoms consistent with heart and spleen deficiency or liver qi stagnation. In clinical research, such as the trial ChiCTR2100042211, it is evaluated alongside other TCM formulas to optimize treatment regimens for GAD compared to standard western medications like buspirone. Its primary therapeutic goals are to stabilize mood, reduce anxiety, and improve sleep quality by balancing internal physiological disharmonies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Anshen Jielv granule.